Merck Sharp + Dohme Corp.

Samantha E Shockley

Rose Yen

Yeon-Hee Lim

James Patrick Roane

Cedric Lorenz Hugelshofer

Jillian R Sanzone

Victor W Mak

Jianming Bao

Fa-Xiang Ding

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Diacylglyceride O-acyltransferase 2 inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Samantha E Shockley